If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

Shares of Insulet Corp. PODD rallied 1.11% to $161.55 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.45% to 7,503.85 and ...

PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin ...

Law Offices of Howard G. Smith reminds investors of the upcoming August 31, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Insulet Corporation ...

The U.S. Food and Drug Administration (FDA) has designated Insulet Corp.’s PODD recall of certain Omnipod insulin delivery ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ:PODD) and certain of the Company's senior executives for ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Insulet Corporation (“Insulet” or ...

PODD carries a Zacks Rank #3 (Hold), a rating designed for a one- to three-month horizon and driven primarily by earnings ...

Insulet Corporation has underperformed the healthcare sector over the past year. However, analysts remain strongly bullish about its prospects.

Insulet Corporation (NASDAQ:PODD) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside ...